{
  "docId": "019de074-7bfd-70c0-985e-370853614892",
  "docSlug": "be9cd2ecd1a9b4702566620e9f2aa170",
  "documentTitle": "Bionomics | Results Presentation Deck | 27 slides",
  "authorId": "bionomics",
  "authorName": "Bionomics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 27,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a numbered list format to present study outcomes across seven clinical domains.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-7bfd-70c0-985e-370853614892/25",
  "deckHref": "/decks/019de074-7bfd-70c0-985e-370853614892",
  "deckJsonHref": "/decks/019de074-7bfd-70c0-985e-370853614892.json",
  "deckAnchorHref": "/decks/019de074-7bfd-70c0-985e-370853614892#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.68,
        "w": 0.94,
        "x": 0.03,
        "y": 0.2
      },
      "kind": "list",
      "text": "1. Efficacy: Is BNC210 is pharmacologically active and potentially efficacious\n2. Primary Outcome: Analysis of SUDS by combination of phases of the public speaking task delivered stronger trends that reached significance in the combined dose arm\n3. Dose Response: No dose separation was observed – BNC210 225 mg will be tested in late-stage trials\n4. Patient Population: Focus on younger adults and potentially adolescents which make up most of the SAD population in the real word\n5. Safety: Safety and tolerability profile is favorable and compatible with a non-sedating anxiolytic\n6. Pharmacokinetics: The new BNC210 tablet formulation delivers a PK profile with rapid onset of effect for acute treatment of social anxiety\n7. Overall Design: PREVAIL was completed in less than a year. The SAD Task performed as expected",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5cb5678-3921-4d94-a3b8-05c8a210f1a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.04,
        "y": 0.11
      },
      "kind": "title",
      "text": "Options for SUDS-based late-stage endpoints were identified and will be discussed with FDA",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64b646bb-f7e3-4108-abe7-975381104178",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "PREVAIL is expected to enable late-stage development of BNC210 in SAD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4cb6824-2495-4d55-9077-caa58cf68bcf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "9b152911-d88d-44e9-b5dc-47e69cd016e9",
      "evidence": "Numbered list of key study findings",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 27,
      "from": 23,
      "beatId": "478e8441-ca9a-4555-beba-f0377b06b183",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "The document concludes with a call to action, outlining next steps and a Q&A session.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 27,
      "from": 23,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "4a7e8e8a-3d2a-47a9-96df-e4aa87ebad49",
      "evidence": "The document concludes with a call to action, emphasizing the importance of next steps in BNC210's development.",
      "position": 1,
      "objective": "To highlight the importance of next steps in BNC210's development",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}